<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82255">
  <stage>Registered</stage>
  <submitdate>3/09/2007</submitdate>
  <approvaldate>21/09/2007</approvaldate>
  <actrnumber>ACTRN12607000479404</actrnumber>
  <trial_identification>
    <studytitle>The protection of left ventricular function during right ventricular pacing.</studytitle>
    <scientifictitle>PROTECT-PACE study: To assess the protection of left ventricular function during right ventricular pacing in patients diagnosed with complete heart block.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Patients diagnosed with high-grade A-V block requiring more than 90% ventricular pacing.</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Implant of pacemaker and lead system. Results after a follow-up period of 24 months will be compared between right ventricular apex (RVA) vs right ventricular high septum (RVHS) lead placement. At the end of the study the treatment continues.

Right ventricular apex: Area at the base of the right ventricle in the heart.
Right ventricular high septum: Area near the top of the right ventricle closer to the middle of the heart.</interventions>
    <comparator>Right ventricular apex lead placement. At the end of the study the treatment continues.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate if RVHS pacing results in significantly improved left ventricular function (as measured by left ventricular ejection fraction) when compared to RVA pacing.</outcome>
      <timepoint>Measured after 24 months of pacing.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate if RVA pacing causes greater degree of left ventricular mechanical dyssynchrony compard to RVHS pacing.</outcome>
      <timepoint>At end of 24 month period.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients diagnosed with high-grade A-V block scheduled to undergo pacemaker implantation.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>-2147483648</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patient with intermittent AV block or scheduled for Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by sealed envelopes</concealment>
    <sequence>Permutated block randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/08/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>238</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Medtronic Australasia</primarysponsorname>
    <primarysponsoraddress>677 High St,
Kew East, Vic, 3102</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Medtronic Inc</fundingname>
      <fundingaddress>4000 Lexington Avenue, 
Shoreview, MN, 55126-2983</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Medtronic UK Ltd.</sponsorname>
      <sponsoraddress>Sherbourne House
Croxley Business Centre, 
Watford, WD18 8WW, UK</sponsoraddress>
      <sponsorcountry>United Kingdom</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>For many years the standard approach to lead placement has been the right ventricular apex (RVA). However, early evidence suggests that right ventricular high septum (RVHS) pacing may be more beneficial compared to RVA pacing. Patients with complete heart block requiring more than 90% ventricular pacing will be randomised into two groups; RVA vs RVHS pacing. The two pacing modalities will be compared to assess left ventricular function as measured by the left ventricular ejection fraction.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Cara Weisbrod</name>
      <address>Medtronic Australasia
Suite 6, 667 High St, Kew East, Vic, 3102</address>
      <phone>+61 3 8851 1016</phone>
      <fax />
      <email>cara.weisbrod@medtronic.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Cara Weisbrod</name>
      <address>Medtronic Australasia
Suite 6, 667 High St, Kew East, Vic, 3102</address>
      <phone>+61 3 8851 1016</phone>
      <fax />
      <email>cara.weisbrod@medtronic.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lilee Chew</name>
      <address>Medtronic Australasia
Suite 6, 667 High St, Kew East, Vic, 3102</address>
      <phone>+61 3 8851 1006</phone>
      <fax />
      <email>lilee.chew@medtronic.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>